Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

In vivo base editing of a humanized mouse model of USH2A as a strategy for treatment of retinitis pigmentosa

Kannan Vrindavan Manian; Ha Eun Cho; Rossano Butcher; Qin Liu; Jason Comander

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):2489.

ARVO Annual Meeting Abstract June 2024

Deep mutational scanning reveals the pathogenicity and structural constraints of a comprehensive set of rhodopsin missense variants

Kannan Vrindavan Manian; Erin Hennessey; Ha Eun; Hilary Scott; Xiaoping Yang; David E Root; Eric A Pierce; Jason Comander

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):457.

ARVO Annual Meeting Abstract June 2023

Base editing approach for in vitro and in vivo evaluation of therapeutic targets in USH2A

Kannan Vrindavan Manian; Yuki Tachida; Erin Hennessey; Rossano Butcher; Eric A Pierce; David R Liu; Qin Liu; Jason Comander

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1912.

ARVO Annual Meeting Abstract June 2020

Cell-autonomous RPE dysfunction is sufficient to instigate CC atrophy and CNV in an iPSC model of Macular Degeneration

Kannan Vrindavan Manian; Sonal Dalvi; Chad A Galloway; Celia Soto; Lauren Winschel; Yiming Li; Danielle S W Benoit; Ruchira Singh

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3809.

ARVO Annual Meeting Abstract July 2019

Dysregulation of MMP2/MMP9 activity by both local (RPE, vasculature) and systemic (serum) factors promotes macular-degeneration-relevant pathological changes in iPSC-derived model(s) of the disease.

Kannan Vrindavan Manian; Sonal Dalvi; Chad A Galloway; Lauren Winschel; Arushi Jain; Celia Soto; Ruchira Singh

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1227.

Advertisement